November 28, 2016
Massachusetts Institute of Technology
By invitation only

The FDA’s Director of the Office of Surveillance and Epidemiology in FDA’s Center for Drug Evaluation and Research will deliver the address, “Assessing the Impact of Postmarketing Regulatory Programs and Actions.”

Gerald J. Dal Pan, MD, MHS currently serves as the Director of the Office of Surveillance and Epidemiology in FDA’s Center for Drug Evaluation and Research, where since 2005 he has been responsible for the Center’s programs in adverse event surveillance and analysis, pharmacoepidemiology, risk management, and medication error prevention. In this capacity, he is involved in both the premarket and postmarket regulation of drugs and therapeutic biologics, and in the implementation of the drug safety provisions of the Food and Drug Administration Amendments Act and other initiatives. He is a member of the World Health Organization Advisory Committee on the Safety of Medicinal Products, and has served on working groups of the Council of International Organization of Medical Sciences (CIOMS) and the International Conference on Harmonisation (ICH). He received his MD from Columbia University College of Physicians and Surgeons and his Master of Health Science in Clinical Epidemiology from the Johns Hopkins University School of Hygiene and Public Health. He completed residency training in Internal Medicine at the Hospital of the University of Pennsylvania and in Neurology at the Johns Hopkins Hospital. He is board certified in both Internal Medicine and Neurology. He joined FDA in 2000 as a medical reviewer in the Center’s Office of New Drugs. Before working at FDA, he was a full-time faculty member in the Department of Neurology at Johns Hopkins and worked in the pharmaceutical industry.

Suggested reading

“Patterns in Spontaneous Adverse Event Reporting Among Branded and Generic Antiepileptic Drugs”

“Methodological Approaches to Evaluate the Impact of FDA Drug Safety Communications”